Haemonetics (HAE)
(Delayed Data from NYSE)
$77.89 USD
-0.19 (-0.24%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $77.82 -0.07 (-0.09%) 7:58 PM ET
2-Buy of 5 2
B Value F Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$77.89 USD
-0.19 (-0.24%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $77.82 -0.07 (-0.09%) 7:58 PM ET
2-Buy of 5 2
B Value F Growth F Momentum F VGM
Zacks News
Haemonetics (HAE) Q3 Earnings Surpass Estimates
by Zacks Equity Research
Haemonetics (HAE) delivered earnings and revenue surprises of 6.78% and -1.14%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Haemonetics (HAE) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Haemonetics (HAE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Perrigo Stock Up as Appeal Date for Irish Tax Bill Nears
by Zacks Equity Research
Perrigo's (PRGO) shares rebound as the time to file an appeal against the Irish tax bill of $1.9 billion nears its deadline of Dec 28.
Perrigo Plunges on $1.9B Tax Bill From Irish Government
by Zacks Equity Research
Perrigo (PRGO), in a SEC filing, reports a $1.9 billion tax bill from Irish revenue department related to its subsidiary, Elan Pharma.
Here's Why You Should Buy Haemonetics (HAE) Stock Right Now
by Zacks Equity Research
Haemonetics (HAE) continues to witness strong growth in Plasma franchise.
Haemonetics (HAE) Down 8.9% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Haemonetics (HAE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Should iShares Morningstar Small-Cap ETF (JKJ) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for JKJ
Haemonetics Strong on Plasma & Hemostasis Management Units
by Zacks Equity Research
Haemonetics (HAE) sees encouraging growth at the North America Plasma revenues on strong disposables along with growing software revenues.
Haemonetics (HAE) Earnings & Revenues Beat Estimates in Q2
by Zacks Equity Research
Haemonetics' (HAE) year-over-year growth in Q2 is backed by benefits from complexity reduction and investments along with strength in market demand and success from early launches.
Will New Products Drive TransEnterix's (TRXC) Q3 Earnings?
by Zacks Equity Research
Among the recent developments, in the third quarter, TransEnterixs (TRXC) gains an FDA approval for its additional 5 millimeter Senhance System instruments.
Can Dental Growth Drive Henry Schein's (HSIC) Q3 Earnings?
by Zacks Equity Research
Henry Schein (HSIC) is well placed to gain from the digitalization trend in the global dental market.
What's Setting the Tone for Hologic's (HOLX) Q4 Earnings?
by Zacks Equity Research
Strength in the Breast Health business, Panther system and increasing utilization of Aptima women's health assays will boost Hologic's (HOLX) top line in Q4.
Will CVS Health's (CVS) PBM Strength Boost Q3 Earnings?
by Zacks Equity Research
Despite a challenging pricing scenario, CVS Health (CVS) is currently gaining on high level of service and execution as well as a competitive pricing along with unique integrated model.
Haemonetics (HAE) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Haemonetics (HAE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
3 Medical Product Stocks to Trump Estimates in Q3 Earnings
by Zacks Equity Research
Here we analyze the favorable factors that are likely to boost results of medical product companies in Q3.
Will Obalon's (OBLN) Q3 Earnings Reflect Growth in U.S.?
by Zacks Equity Research
Obalon (OBLN) is expected to register robust U.S. revenues in Q3, backed by higher reorders from existing accounts and new order bookings.
What's in Store for Integer Holdings (ITGR) in Q3 Earnings?
by Zacks Equity Research
The Cardio & Vascular product line to boost Integer Holdings' (ITGR) top line in Q3. The upside will be driven by strong revenues in the peripheral vascular, neurovascular and electrophysiology markets.
ResMed (RMD) Looks Good: Stock Adds 5.7% in Session
by Zacks Equity Research
ResMed (RMD) shares rose nearly 6% in the last trading session, amid huge volumes.
Should iShares Morningstar Small-Cap ETF (JKJ) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for JKJ
Should iShares Morningstar Small-Cap ETF (JKJ) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for JKJ
Why Is Haemonetics (HAE) Up 9.2% Since Last Earnings Report?
by Zacks Equity Research
Haemonetics (HAE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Haemonetics Strong on Plasma Unit Amid Blood Center Weakness
by Zacks Equity Research
Haemonetics (HAE) witnesses strong growth in Plasma franchise. Dullness in Blood Center business prevails.
Cardiovascular Systems Posts 2-Year LIBERTY 360 Study Data
by Zacks Equity Research
The 24-month outcome of LIBERTY 360 study by Cardiovascular Systems (CSII) demonstrates a constant relief from major amputation across all Rutherford Classifications (RC).
Haemonetics (HAE) Q1 Earnings & Revenues Beat Estimates
by Zacks Equity Research
Haemonetics' (HAE) year-over-year growth is backed by the solid execution of its multi-year turnaround strategy.
Zacks.com highlights: Lululemon Athletica, Sirius XM Holdings, Haemonetics, Lockheed Martin and ConocoPhillips
by Zacks Equity Research
Zacks.com highlights: Lululemon Athletica, Sirius XM Holdings, Haemonetics, Lockheed Martin and ConocoPhillips